| A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants (NCT05412030) | GlaxoSmithKline | 2022-06-16 |
| Serotype Distribution in Hospitalized Adult With Pneumococcal Community Acquired Pneumonia in France (NCT05380193) | Institut National de la Santé Et de la Recherche Médicale, France | 2022-05-09 |
| A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine (NCT04989465) | Sinovac Biotech Co., Ltd | 2021-09-10 |
| Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients (NCT04875858) | Korea University Guro Hospital | 2021-05-01 |
| Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV (NCT04875819) | Thomas Benfield | 2021-04-28 |
| Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i) (NCT04841369) | CanSino Biologics Inc. | 2021-04-13 |
| Evaluation of Prime-boost Anti-pneumococcal Vaccination in Patients With Diffuse Large B Cell Lymphoma Treated With Rituximab (NCT04214444) | University Hospital, Tours | 2020-07-03 |
| Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033) (NCT04384107) | Merck Sharp & Dohme LLC | 2020-07-01 |
| Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (NCT04100772) | CanSino Biologics Inc. | 2020-05-18 |
| Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED) (NCT03921424) | Merck Sharp & Dohme LLC | 2019-11-05 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) (NCT04031846) | Merck Sharp & Dohme LLC | 2019-09-04 |
| Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026) (NCT04016714) | Merck Sharp & Dohme LLC | 2019-08-28 |
| Impact of Pharmacist-led Educational Intervention on Pneumococcal Vaccination Rates in Cancer Patients (NCT05229081) | Hacettepe University | 2019-07-19 |
| Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) (NCT03885934) | Merck Sharp & Dohme LLC | 2019-06-25 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (NCT03893448) | Merck Sharp & Dohme LLC | 2019-06-19 |
| Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE) (NCT03950622) | Merck Sharp & Dohme LLC | 2019-06-13 |
| Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020) (NCT03950856) | Merck Sharp & Dohme LLC | 2019-06-12 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028) (NCT03848065) | Merck Sharp & Dohme LLC | 2019-04-02 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE) (NCT03731182) | Merck Sharp & Dohme LLC | 2019-01-23 |
| A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK) (NCT03692871) | Merck Sharp & Dohme LLC | 2018-12-14 |
| A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) (NCT03620162) | Merck Sharp & Dohme LLC | 2018-10-18 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU) (NCT03615482) | Merck Sharp & Dohme LLC | 2018-09-14 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM) (NCT03565900) | Merck Sharp & Dohme LLC | 2018-09-12 |
| Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age (NCT03642847) | Pfizer | 2018-08-29 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY) (NCT03547167) | Merck Sharp & Dohme LLC | 2018-07-16 |
| A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years. (NCT03571607) | Pfizer | 2018-07-12 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018) (NCT03480802) | Merck Sharp & Dohme LLC | 2018-07-06 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) (NCT03480763) | Merck Sharp & Dohme LLC | 2018-06-22 |
| Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants (NCT03550313) | Pfizer | 2018-06-01 |
| Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants (NCT03512288) | Pfizer | 2018-04-16 |
| Immunization To Prevent Acute COPD Exacerbations (NCT03276754) | Pfizer | 2017-11-30 |
| Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels (NCT02637583) | Jena University Hospital | 2017-10-18 |
| A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age (NCT03313050) | Pfizer | 2017-10-12 |
| Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age (NCT03313037) | Pfizer | 2017-10-10 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008) (NCT02987972) | Merck Sharp & Dohme LLC | 2017-03-21 |
| A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years (NCT02955160) | Pfizer | 2016-11-03 |
| A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults (NCT02892812) | LG Life Sciences | 2016-09-01 |
| PCV13 in Non-pregnant Papua New Guinean Women (NCT04183322) | Telethon Kids Institute | 2016-05-10 |
| Immunogenicity and Safety Study of NBP606 in Healthy Toddlers (NCT02927444) | SK Chemicals Co., Ltd. | 2015-11-04 |
| Enhancing a Sustainable Pharmacy-based Immunization Program in Two States (NCT02615470) | Auburn University | 2015-11-01 |
| An Incitative Multifaceted PROcedure for Pneumococcal Vaccination at the Emergency Department (NCT01899365) | Centre Hospitalier Princesse Grace | 2015-11-01 |
| Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007) (NCT02573181) | Merck Sharp & Dohme LLC | 2015-10-30 |
| Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006) (NCT02547649) | Merck Sharp & Dohme LLC | 2015-10-08 |
| A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005) (NCT02531373) | Merck Sharp & Dohme LLC | 2015-09-15 |
| Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly (NCT02451969) | Sinovac Biotech Co., Ltd | 2015-04-01 |
| Systematic Search for Primary Immunodeficiency in Adults With Infections (NCT02972281) | University Hospital, Lille | 2015-03-01 |
| Antibodies and Memory Cells Role After Different Pneumococcal Vaccines in HIV Adults (NCT02357823) | University of Siena | 2015-01-01 |
| Immunogenicity and Safety Study of NBP606 in Healthy Infants (NCT02201030) | SK Chemicals Co., Ltd. | 2014-09-06 |
| Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae (NCT02116998) | Genocea Biosciences, Inc. | 2014-09-01 |
| Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029) (NCT02225587) | Merck Sharp & Dohme LLC | 2014-08-28 |
| Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses (NCT02012309) | University of Colorado, Denver | 2014-08-01 |
| Surveillance of Invasive Pneumococcal Infections in Adults (Excluding Meningitis) (NCT03983616) | University Hospital, Limoges | 2014-04-12 |
| Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004) (NCT02037984) | Merck Sharp & Dohme LLC | 2014-01-28 |
| Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (NCT02079207) | SK Chemicals Co., Ltd. | 2013-12-01 |
| Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine (NCT03552445) | Korea University Guro Hospital | 2013-11-01 |
| MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine (NCT02225327) | Korea University Guro Hospital | 2013-10-01 |
| Immunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso (NCT01577771) | Agence de Médecine Préventive, France | 2013-02-01 |
| Influenza Vaccine and Pneumococcal Vaccine (NCT02582047) | Korea University Guro Hospital | 2012-10-01 |
| The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002) (NCT01513551) | Merck Sharp & Dohme LLC | 2012-03-13 |
| Serological Response to Antipneumococcal Vaccination and Impact on Streptococcus Pneumoniae Nasal Carriage in HIV Adults (NCT02123433) | University of Siena | 2011-12-01 |
| Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants (NCT01446926) | Sanofi Pasteur, a Sanofi Company | 2011-09-01 |
| 13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico (NCT01432262) | Pfizer | 2011-07-01 |
| Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage (NCT01311024) | Arto Palmu | 2011-04-01 |
| National, Non Interventional Study of Invasive Pneumococcal Disease in Children and Newborns (NCT04664556) | Association Clinique Thérapeutique Infantile du val de Marne | 2010-12-13 |
| A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003) (NCT01215188) | Merck Sharp & Dohme LLC | 2010-10-14 |
| A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria (NCT01193582) | Pfizer | 2010-09-01 |
| Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults (NCT01444352) | Sanofi Pasteur, a Sanofi Company | 2010-06-01 |
| Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine (NCT00962780) | Pfizer | 2010-03-01 |
| Study of Two Investigational Pneumococcal Vaccines in Healthy Adults (NCT01444339) | Sanofi | 2010-02-01 |
| Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10 (NCT04912297) | Finnish Institute for Health and Welfare | 2009-11-12 |
| Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS (NCT00963235) | Pfizer | 2009-11-01 |
| Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001) (NCT01215175) | Merck Sharp & Dohme LLC | 2009-09-25 |
| Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47 (NCT00873431) | Valneva Austria GmbH | 2009-03-01 |
| Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults (NCT00744263) | Pfizer | 2008-09-01 |
| Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects (NCT00500266) | Pfizer | 2008-05-01 |
| Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life (NCT00625677) | Public Health England | 2008-02-01 |
| Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization (NCT00508742) | Pfizer | 2007-12-01 |
| Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) (NCT00546572) | Wyeth is now a wholly owned subsidiary of Pfizer | 2007-11-01 |
| Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults (NCT00492557) | Pfizer | 2007-09-01 |
| Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children (NCT00452452) | Wyeth is now a wholly owned subsidiary of Pfizer | 2007-07-01 |
| Pneumococcal Reference Standard (NCT00479323) | National Institute of Allergy and Infectious Diseases (NIAID) | 2007-06-01 |
| Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults (NCT00427895) | Pfizer | 2007-02-27 |
| Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers (NCT01444001) | Sanofi | 2007-02-01 |
| Study Evaluating Streptococcus Pneumoniae Nasopharyngeal Carriage Rate in Children Receiving Prevnar® (NCT00488371) | Wyeth is now a wholly owned subsidiary of Pfizer | 2006-11-01 |
| Safety and Local Tolerability of Prevenar in Indian Children (NCT00488800) | Wyeth is now a wholly owned subsidiary of Pfizer | 2006-07-01 |
| PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers (NCT00714064) | Menzies School of Health Research | 2006-06-01 |
| PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers to See if it Protects Their Babies From Ear Disease (NCT00310349) | University of Melbourne | 2006-03-01 |
| Long-term Impact of Pneumococcal Conjugate Vaccine on Carriage (NCT00294021) | Johns Hopkins Bloomberg School of Public Health | 2006-03-01 |
| Pneumococcal Vaccination of Fiji Infants (NCT00170612) | University of Melbourne | 2005-11-01 |
| Study Evaluating 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants (NCT00488826) | Wyeth is now a wholly owned subsidiary of Pfizer | 2005-10-01 |
| Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media (NCT00195611) | Wyeth is now a wholly owned subsidiary of Pfizer | 2005-09-01 |
| Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines (NCT00197808) | Public Health England | 2005-04-01 |
| A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013) (NCT00127153) | Merck Sharp & Dohme LLC | 2005-03-01 |
| Study Evaluating Prevenar Vaccine in Healthy Infants (NCT00276107) | Wyeth is now a wholly owned subsidiary of Pfizer | 2004-12-01 |
| Study Evaluating Pneumococcal Vaccine in Healthy Infants (NCT00205803) | Wyeth is now a wholly owned subsidiary of Pfizer | 2004-09-01 |
| Early Versus Delayed Pneumococcal Vaccination in HIV (NCT00137605) | CIHR Canadian HIV Trials Network | 2004-09-01 |
| Mother's Gift Project (NCT00142389) | Johns Hopkins Bloomberg School of Public Health | 2004-08-01 |
| Immunogenicity of PCV-7 Vaccine in VLBW Infants (NCT00273325) | NICHD Neonatal Research Network | 2004-07-01 |
| Study Investigating Administration of Prevenar for Post-Marketing Surveillance (NCT00195390) | Wyeth is now a wholly owned subsidiary of Pfizer | 2004-07-01 |
| Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine (NCT00164411) | Centers for Disease Control and Prevention | 2004-01-01 |